Market Place
Sourcing Support
Innovent Announces 2025 Annual Results And Business Updates
26 Mar 2026 //
PR NEWSWIRE
Innovent`s Weight-Loss Drug Highlights China Challenge for Novo
22 Sep 2025 //
REUTERS
Fangzhou, Innovent Bio Form Alliance for AI Weight Management
10 Sep 2025 //
GLOBENEWSWIRE
Lilly, Innovent`s Mazdutide Nabs First-In-Class Nod in China
28 Jun 2025 //
FIERCE PHARMA
Ph 3 Mazdutide Obesity Study Published in NEJM
25 May 2025 //
PR NEWSWIRE
Innovent Released 2024 ESG Report, Underscoring Commitment to Sustainable
19 May 2025 //
PR NEWSWIRE
GLORY-3: Second Phase 3 Study of Mazdutide vs Semaglutide Begins
15 May 2025 //
PR NEWSWIRE
Innovent Presents At 43rd J.P. Morgan Healthcare Conference
16 Jan 2025 //
PR NEWSWIRE
Innovent’s Dovbleron Gets Second NDA Approval from NMPA
02 Jan 2025 //
PR NEWSWIRE
Innovent & Lilly Expand Collaboration for Jaypirca
16 Dec 2024 //
PR NEWSWIRE
Innovent`s NDA For Picankibart Accepted By NMPA
26 Sep 2024 //
PR NEWSWIRE
Innovent Receives Fast Track Designation from FDA for Advanced Melanoma
03 Sep 2024 //
PR NEWSWIRE
Innovent Annouces Multiple Clinical Study Results of Mazdutide
01 Sep 2024 //
PR NEWSWIRE
Innovent Announces 2024 Interim Results and Business Updates
28 Aug 2024 //
PR NEWSWIRE
Innovent To Present Clinical Data At WCLC And ESMO 2024
28 Aug 2024 //
PR NEWSWIRE
Innovent`s KRAS G12C Inhibitor First Approved In China
22 Aug 2024 //
PR NEWSWIRE
Innovent`s Mazdutide NDA For Type 2 Diabetes Accepted By NMPA
01 Aug 2024 //
PR NEWSWIRE
Innovent bags another phase 3 win in China for next-gen Lilly GLP-1 drug
23 Jul 2024 //
BIOSPACE
Innovent Launches ESG Website To Enhance Sustainability And Responsibility
07 Jul 2024 //
PR NEWSWIRE
Innovent links IL-2 fusion protein to responses in small study
15 Jun 2024 //
FIERCE PHARMA
Innovent Presents IBI363 Bispecific Data In Advanced NSCLC At ESMO 2024
13 Jun 2024 //
PR NEWSWIRE
Innovent looks to Chinese regulators after ph. 3 psoriasis win
28 May 2024 //
FIERCE BIOTECH
Lilly`s next-gen obesity drug brings Innovent ph. 3 diabetes win
09 May 2024 //
FIERCE BIOTECH
Innovent`s Phase III obesity treatment trial meets all endpoints
10 Jan 2024 //
CLINICAL TRIALS ARENA
Next-gen Lilly obesity drug secures first phase 3 win for Innovent
09 Jan 2024 //
FIERCE BIOTECH
Innovent showcases topline PhII win for high-dose obesity drug in China
11 May 2023 //
ENDPTS
Innovent Announces Updated Data of Ph1 Trial for IBI351 (KRAS[G12C] Inhibitor
17 Apr 2023 //
PR NEWSWIRE
Innovent pays nearly $100M for China rights to LG Chem gout med
15 Dec 2022 //
FIERCEBIOTECH
Innovent and LG Chem Announce Strategic Collaboration for Tigulixostat
14 Dec 2022 //
PRNEWSWIRE
Innovent Presents Phase 1b Clinical Data of IBI188 at the 2022 ASH
10 Dec 2022 //
PRNEWSWIRE
Innovent Presents Phase Ib Clinical Data Update of IBI110m at European Society
08 Dec 2022 //
PRNEWSWIRE
Innovent & UNION Announce First Subject Dosed in a Chinese PhI Study Orismilast
04 Dec 2022 //
PRNEWSWIRE
Innovent Announced Data of Multiple Trials Will be Presented at ESMO-IO and ASH
27 Nov 2022 //
PRNEWSWIRE
Innovent Announces First Participant Dosed in a Phase 3 Study of Mazdutide
14 Nov 2022 //
PRNEWSWIRE
Innovent Releases Results of a Phase 3 Study of Tafolecimab in Chinese Patients
06 Nov 2022 //
PRNEWSWIRE
Innovent begins subject dosing in Phase I solid tumour therapy trial
31 Oct 2022 //
CLINICALTRIALSARENA
Innovent Announces First Patient Dosing in Australia in Phase I Study of IBI343
30 Oct 2022 //
PRNEWSWIRE
Innovent Announces Phase Ib Results of Higher-dose Mazdutide (IBI362)
16 Oct 2022 //
PRNEWSWIRE
The China NMPA Approves Selpercatinib for the Treatment of Lung Cancers
09 Oct 2022 //
PRNEWSWIRE
Innovent`s Sintilimab plus Chemotherapy Demonstrated PFS Benefit in Patients
07 Sep 2022 //
PRNEWSWIRE
Innovent doses first subject in Phase II trial of mazdutide for obesity
05 Sep 2022 //
CLINICALTRIALSARENA
Innovent Announces First Participant Dosed in the PII Trial of Mazdutide
04 Sep 2022 //
PRNEWSWIRE
Innovent begins patient dosing in Australia in phase 1 study of IBI363
25 Aug 2022 //
PHARMABIZ
Innovent Announced 2022 Interim Results and Business Updates
25 Aug 2022 //
PRNEWSWIRE
Innovent Begins Dosing in PI Study of IBI311
17 Aug 2022 //
PRNEWSWIRE
Pursuing AbbVie and J&J, Innovent hits primary endpoint in phase 2 trial
10 Aug 2022 //
FIERCE BIOTECH
Innovent`s PII Study of Picankibart in Plaque Psoriasis Met Primary Endpoint
09 Aug 2022 //
PRNEWSWIRE
Innovent Begins Dosing in PI Study of IBI324 in Diabetic Macular Edema
07 Aug 2022 //
PRNEWSWIRE
Sanofi and Innovent Biologics to collaborate on oncology medicines
05 Aug 2022 //
LABIOTECH
Innovent and Laekna begin Dosing with Three-drug Combination in PI/II Study
31 Jul 2022 //
PRNEWSWIRE
NMPA Grants Priority Review to Innovent and Ascentage`s NDA for Olverembatinib
19 Jul 2022 //
PRNEWSWIRE
Innovent Begins Dosing in PII study of IBI112 in Active Ulcerative Colitis
04 Jul 2022 //
ASIAONE
Innovent Announces PIb Study Results of Mazdutide in Chinese Patients with T2D
28 Jun 2022 //
PRNEWSWIRE
Innovent and Lilly Jointly Announce the Approval of TYVYT by China NMPA
20 Jun 2022 //
PRNEWSWIRE
Innovent Announces the NMPA Acceptance of NDA for Tafolecimab Injection
13 Jun 2022 //
PRNEWSWIRE
Innovent and Etana Announce the Approval of Bevagen by Indonesian FDA
13 Jun 2022 //
PRNEWSWIRE
Innovent Releases Results of High-dose Cohorts in PI Study of Mazdutide
12 Jun 2022 //
PRNEWSWIRE
IASO Bio and Innovent Present Updated Data of BCMA CAR-T Cell Therapy
12 Jun 2022 //
PRNEWSWIRE
Innovent Announces PII study of Mazdutide?IBI362? in Chinese Participants
07 Jun 2022 //
PRNEWSWIRE
AnHeart & Innovent Present Updated PII Efficacy and Safety Data of Taletrectinib
06 Jun 2022 //
BUSINESSWIRE
